Pacira price target lowered to $37 from $41 at Raymond James

Raymond James lowered the firm’s price target on Pacira to $37 from $41 and keeps an Outperform rating on the shares. Pacira reported solid Q2 results, but the focus remains on the judge’s decision for the first Exparel patent case expected by August 1, the analyst tells investors in a research note. Regardless of the outcome, Pacira feels there is a very long road ahead with numerous patents for the recently approved generic still to navigate around, the firm notes.